APNHY
Price
$5.45
Change
-$0.39 (-6.68%)
Updated
Sep 25 closing price
Capitalization
2.57B
BIOYF
Price
$8.50
Change
-$0.00 (-0.00%)
Updated
Sep 25 closing price
Capitalization
96.09M
Interact to see
Advertisement

APNHY vs BIOYF

Header iconAPNHY vs BIOYF Comparison
Open Charts APNHY vs BIOYFBanner chart's image
Aspen Pharmacare Holdings
Price$5.45
Change-$0.39 (-6.68%)
Volume$640
Capitalization2.57B
BioSyent
Price$8.50
Change-$0.00 (-0.00%)
Volume$200
Capitalization96.09M
APNHY vs BIOYF Comparison Chart in %
Loading...
APNHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIOYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APNHY vs. BIOYF commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APNHY is a Hold and BIOYF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (APNHY: $5.45 vs. BIOYF: $8.50)
Brand notoriety: APNHY and BIOYF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: APNHY: 39% vs. BIOYF: 13%
Market capitalization -- APNHY: $2.57B vs. BIOYF: $96.09M
APNHY [@Pharmaceuticals: Generic] is valued at $2.57B. BIOYF’s [@Pharmaceuticals: Generic] market capitalization is $96.09M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APNHY’s FA Score shows that 1 FA rating(s) are green whileBIOYF’s FA Score has 1 green FA rating(s).

  • APNHY’s FA Score: 1 green, 4 red.
  • BIOYF’s FA Score: 1 green, 4 red.
According to our system of comparison, BIOYF is a better buy in the long-term than APNHY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APNHY’s TA Score shows that 4 TA indicator(s) are bullish while BIOYF’s TA Score has 5 bullish TA indicator(s).

  • APNHY’s TA Score: 4 bullish, 4 bearish.
  • BIOYF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, APNHY is a better buy in the short-term than BIOYF.

Price Growth

APNHY (@Pharmaceuticals: Generic) experienced а -4.68% price change this week, while BIOYF (@Pharmaceuticals: Generic) price change was -2.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.88%. For the same industry, the average monthly price growth was +23.85%, and the average quarterly price growth was +67.10%.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APNHY($2.57B) has a higher market cap than BIOYF($96.1M). BIOYF has higher P/E ratio than APNHY: BIOYF (16.57) vs APNHY (10.28). BIOYF YTD gains are higher at: 11.220 vs. APNHY (-33.989). APNHY has higher annual earnings (EBITDA): 2.16B vs. BIOYF (12M). APNHY has more cash in the bank: 6.41B vs. BIOYF (20.4M). BIOYF has less debt than APNHY: BIOYF (942K) vs APNHY (36.1B). APNHY has higher revenues than BIOYF: APNHY (43.4B) vs BIOYF (39.5M).
APNHYBIOYFAPNHY / BIOYF
Capitalization2.57B96.1M2,675%
EBITDA2.16B12M18,008%
Gain YTD-33.98911.220-303%
P/E Ratio10.2816.5762%
Revenue43.4B39.5M109,873%
Total Cash6.41B20.4M31,417%
Total Debt36.1B942K3,832,272%
FUNDAMENTALS RATINGS
APNHY vs BIOYF: Fundamental Ratings
APNHY
BIOYF
OUTLOOK RATING
1..100
625
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
26
Undervalued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
9942
PRICE GROWTH RATING
1..100
8658
P/E GROWTH RATING
1..100
9160
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APNHY's Valuation (7) in the null industry is in the same range as BIOYF (26). This means that APNHY’s stock grew similarly to BIOYF’s over the last 12 months.

BIOYF's Profit vs Risk Rating (42) in the null industry is somewhat better than the same rating for APNHY (100). This means that BIOYF’s stock grew somewhat faster than APNHY’s over the last 12 months.

BIOYF's SMR Rating (42) in the null industry is somewhat better than the same rating for APNHY (99). This means that BIOYF’s stock grew somewhat faster than APNHY’s over the last 12 months.

BIOYF's Price Growth Rating (58) in the null industry is in the same range as APNHY (86). This means that BIOYF’s stock grew similarly to APNHY’s over the last 12 months.

BIOYF's P/E Growth Rating (60) in the null industry is in the same range as APNHY (91). This means that BIOYF’s stock grew similarly to APNHY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APNHYBIOYF
RSI
ODDS (%)
Bullish Trend 1 day ago
69%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
66%
Bullish Trend 1 day ago
45%
Momentum
ODDS (%)
Bearish Trend 1 day ago
54%
Bearish Trend 1 day ago
38%
MACD
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
45%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
60%
Bearish Trend 1 day ago
37%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
60%
Bearish Trend 1 day ago
40%
Advances
ODDS (%)
Bullish Trend 5 days ago
67%
Bullish Trend 18 days ago
47%
Declines
ODDS (%)
Bearish Trend 10 days ago
57%
Bearish Trend 8 days ago
40%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
66%
Bearish Trend 3 days ago
56%
Aroon
ODDS (%)
Bearish Trend 1 day ago
48%
Bullish Trend 1 day ago
33%
View a ticker or compare two or three
Interact to see
Advertisement
APNHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIOYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EMNSF2.13N/A
N/A
Elementis PLC
NEXPF5.51N/A
N/A
NEXI S.P.A.
RBGPF76.43N/A
N/A
Reckitt Benckiser Group Plc.
PGNT5.23-0.02
-0.42%
Paragon Technologies, Inc.
HAIVF3.49-0.15
-4.25%
HAIVISION SYS INC .

APNHY and

Correlation & Price change

A.I.dvisor tells us that APNHY and TRUFF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APNHY and TRUFF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APNHY
1D Price
Change %
APNHY100%
-6.64%
TRUFF - APNHY
21%
Poorly correlated
-13.49%
PRFX - APNHY
20%
Poorly correlated
-6.71%
ESALF - APNHY
20%
Poorly correlated
-0.16%
SDZNY - APNHY
20%
Poorly correlated
-1.78%
BIOVF - APNHY
19%
Poorly correlated
N/A
More

BIOYF and

Correlation & Price change

A.I.dvisor tells us that BIOYF and BUDZ have been poorly correlated (+6% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOYF and BUDZ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOYF
1D Price
Change %
BIOYF100%
N/A
BUDZ - BIOYF
6%
Poorly correlated
-3.23%
AVCNF - BIOYF
1%
Poorly correlated
+1.68%
APNHY - BIOYF
0%
Poorly correlated
-6.64%
BSPK - BIOYF
0%
Poorly correlated
-6.90%
BIOVF - BIOYF
0%
Poorly correlated
N/A
More